紫杉醇联合奥沙利铂和顺铂治疗进展期非小细胞肺癌的疗效对比观察

目的观察紫杉醇联合奥沙利铂方案治疗进展期非小细胞肺癌(NSCLC)的疗效、毒副反应。方法将50例晚期NSCLC患者分为两组。对照组25例,紫杉醇135mg/m2,d1,d8;顺铂75mg/m2,d1～d2。奥沙利铂组25例,紫杉醇用法同顺铂组,奥沙利铂130 mg/m2,d1,均为静脉滴入,21d为1个疗程。评价有效率、不良反应及生活质量。结果对照组与治疗组的有效率分别为20.0%和36.0%,差异有统计学意义(P<0.05)。对照组胃肠道反应发生率高于治疗组(P<0.05),神经毒性发生率低于奥沙利铂组(P<0.05),生活质量方面,治疗组KPS评分高于对照组,两组比较差异有统计学意义(P<0.05)。结论紫杉醇联合奥沙利铂是治疗进展期NSCLC的有效方案。紫杉醇联合奥沙利铂铂方案毒副作用小,特别是消化道反应弱,患者易于接受,依从性高,能明显提高患者的生存质量。

A Randomized Clinical Trial of Che Motherapy Combined with Oxaliplatin and Cisplatin Plus Paclitaxel in the Treatment of Advanced Non-small Cell Lung Cancer

Objective Observation the difference of efficacy,side effects and quality of life in advanced non small cell lung cancer（NSCLC） patients treated with Paclitaxel plus oxaliplatin or cisplatin.Methods The 50 patients with advanced NSCLC were divided into two groups.25 patients in control group,paclitaxel 135mg/m2,d1,d8;cisplatin 75mg/m2,d1-d2.25 patients with oxaliplatin,paclitaxel with cisplatin use,oxaliplatin 130 mg/m2,d1,both intravenous infusion,21d of a course of treatment.Evaluation of efficiency,adverse reactions and quality of life.Results The rates of Control group and treatment group,were 20% and 48%,the difference was statistically significant（P0.05）.the incidence of gastrointestinal reactions were higher in Control group than those in treatment group（P0.05）.While in peripheral nerve toxicity,the oxaliplatin group was higher than the cisplatin group（P0.05）,in Quality of life,the KPS of treatment group score higher than those in treatment group（P0.05）.Conclusion Paclitaxel and oxaliplatin are an effective program of treatment of advanced NSCLC.Side effects is small,especially inGastrointestinal reactions,it is weak,the program accepted easily by patients,have a high compliance,can significantly improve the patients quality of life.